VERAXA Biotech (NASDAQ: VRXA) announced on July 20 that it has received Scientific Advice from Germany’s Paul-Ehrlich-Institute (PEI), providing regulatory feedback on the biological rationale and proposed non-clinical development strategy for its lead BiTAC®-TCE program. This milestone marks progress for the company as it advances its proprietary bispecific T-cell engager platform toward clinical development.
The Scientific Advice procedure allows drug developers to consult with regulatory experts before initiating clinical trials, helping to align development strategies with regulatory expectations. According to the company, the feedback provides early guidance on its biological rationale, safety assessments, and non-clinical development plan, which could reduce development uncertainty by providing greater clarity before advancing toward clinical studies. The company believes this regulatory input helps mitigate risks associated with early-stage drug development.
VERAXA’s lead BiTAC®-TCE candidate previously generated encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The company continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (ADCs), and other engineered antibody formats. The latest regulatory milestone follows continued progress in manufacturing and development as the company advances next-generation antibody therapeutics for cancer.
Investors can find the full announcement and additional details in the company’s newsroom at https://ibn.fm/VRXA. The company also provided a link to the press release containing the Scientific Advice announcement at https://ibn.fm/zBiDU.
Forward-looking statements in this announcement are subject to risks and uncertainties, including those described in the company’s filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements unless required by law.
